New hope for rare adrenal cancer: drug trial launches
NCT ID NCT07282587
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called ONC206 in 90 people with advanced pheochromocytoma or paraganglioma, rare tumors of the adrenal glands. Participants must have tumors that cannot be removed by surgery and have not responded to or cannot have standard treatments. The study will measure how many patients' tumors shrink or disappear, and how long that effect lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONC206 (a drug taken by mouth)
What this could lead to
If successful, this could provide a new treatment option for people with rare adrenal tumors that have stopped responding to standard therapies.
What could go wrong
This is a mid-stage trial with only 90 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
NOT_YET_RECRUITINGNew York, New York, 10032, United States
-
Mayo-Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
PENN
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Stanford
RECRUITINGPalo Alto, California, 94604, United States
-
U of Colorado
RECRUITINGAurora, Colorado, 80045, United States
-
U of Michigan
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109, United States
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
-
UTAH
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States